15 not yet recruiting. 15 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Not yet recruiting 15 |
| Phase 2 | 4 | Not yet recruiting 4 |
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis | Phase 1 | Not yet recruiting | AbelZeta Inc. | 12 | 2027-03-01 | 2026-10-13 |
| Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases HN2302 Injection - Autoimmune Disease, Systemic Lupus Erythematosus | Phase 1 | Not yet recruiting | Shenzhen MagicRNA Biotechnology Co., Ltd | 12 | 2026-12-31 | 2026-08-12 |
| Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases anti-CD19 CAR-T cells - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 1 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 6 | 2026-12-01 | 2026-09-02 |
| A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases QLS2416 Injection - Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA) | Phase 1 | Not yet recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | 76 | 2026-12-01 | 2026-10-30 |
| A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Not yet recruiting | Pfizer | 54 | 2026-11-19 | 2026-10-01 |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease LMY-922 - Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE) | Phase 1 | Not yet recruiting | Luminary Therapeutics | 94 | 2026-10-01 | 2026-07-28 |
| Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases Allogeneic CD19/BCMA-targeted CAR-γδT cell injection, Cyclophosphamide, Fludarabine - Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 9 | 2026-07-01 | 2026-06-09 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic Sclerosis HS_SW01 cells injection - Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Huishan Biotechnology Co., Ltd. | 21 | 2026-04-10 | 2026-04-21 |
| YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis | Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 12 | 2026-03-01 | 2026-02-27 |
| UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases universal allogeneic anti-CD19/BCMA CAR T-cells - Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Changzhou No.2 People's Hospital | 18 | 2025-05-01 | 2025-05-18 |
| Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic Sclerosis 2 infusions of MSC, 1 infusion of MSC, Placebo - Severe Systemic Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 18 | 2024-12-01 | 2024-12-09 |
| 89Zr-Oxine-RY_SW01 Cell Injection for the Treatment of Systemic Sclerosis 89Zr-Oxine-RY_SW01 Cell Injection - Systemic Sclerosis | Phase 1 | Not yet recruiting | Jiangsu Renocell Biotech Company | 8 | 2024-06-30 | 2024-07-08 |
Lupus Erythematosus, Systemic (9) · Myositis (6) · Arthritis, Rheumatoid (5) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (4) · Autoimmune Diseases (4) · Scleroderma, Diffuse (4) · Sjogren's Syndrome (4) · Dermatomyositis (2) · Lupus Nephritis (2) · Myasthenia Gravis (2) · Anemia, Hemolytic, Autoimmune (1) · Antiphospholipid Syndrome (1) · Dry Eye Syndromes (1) · Immunoglobulin G4-Related Disease (1)
Connective Tissue Diseases (15) · Skin Diseases (15) · Skin and Connective Tissue Diseases (15) · Immune System Diseases (12) · Autoimmune Diseases (8) · Musculoskeletal Diseases (8) · Nervous System Diseases (8) · Neuromuscular Diseases (8) · Arthritis (7) · Joint Diseases (7) · Muscular Diseases (7) · Rheumatic Diseases (7) · Eye Diseases (5) · Cardiovascular Diseases (4) · Lacrimal Apparatus Diseases (4)
Cyclophosphamide (1) · fludarabine (1)
AbelZeta Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Bristol-Myers Squibb (1) · Changzhou No.2 People's Hospital (1) · Children's Hospital of Fudan University (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Jiangsu Renocell Biotech Company (1) · Luminary Therapeutics (1) · Peking University Third Hospital (1) · Pfizer (1) · Shanghai Qilu Pharmaceutical Research and Development Center LTD (1) · Shenzhen Huishan Biotechnology Co., Ltd. (1) · Shenzhen MagicRNA Biotechnology Co., Ltd (1) · The Affiliated Hospital of Qingdao University (1)
China (4) · United States (3) · France (2) · Belgium (1) · Germany (1) · Netherlands (1) · Poland (1)
Yihong Yao, PhD (1) · Zhu Chen (1)